Introduction: The prognosis of advanced hepatocellular carcinoma (HCC) varies in patients receiving transcatheter arterial chemoembolization (TACE). In this study, we aimed to assess the prognostic value of serum apolipoprotein B (ApoB)/apolipoprotein A-I (ApoA-I) in this group of patients. Methods: The serum lipid levels of HCC patients undergoing TACE were obtained from routine preoperative blood lipid examination. A propensity score-matched (PSM) analysis was used to eliminate the imbalance of baseline characteristics of the high and low ApoB/ApoA-I groups. Then, univariate and multivariate analysis were conducted to evaluate the prognostic value of ApoB/ApoA-I. Results: In 455 HCC patients treated with TACE, ApoB/ApoA-I was positively correlated with AFP, T stage, distant metastasis, and TNM stage (p #x3c; 0.05). Patients with high ApoB/ApoA-I had a significantly shorter overall survival (OS) than those with low ApoB/ApoA-I (median OS, 21.7 vs. 39.6 months, p #x3c; 0.001). Multivariate analysis indicated that ApoB/ApoA-I was an independent prognostic index for OS (hazard ratio [HR] = 1.42, p = 0.008). After baseline characteristics were balanced, 288 patients were included in the PSM cohort. In this cohort, high ApoB/ApoA-I still predicted inferior OS in both univariate analysis (median OS, 27.6 vs. 39.3 months, p = 0.002) and multivariate analysis (HR = 1.58, p = 0.006). Conclusion: Serum ApoB/ApoA-I is a useful biomarker in predicting aggressive clinicopathological characteristics and poor prognosis in HCC patients treated with TACE.
Oncol Res Treat

中文翻译：

---

经导管动脉化疗栓塞治疗肝细胞癌患者血清载脂蛋白 B 与载脂蛋白 AI 比值的预后价值：倾向评分匹配分析

简介：接受经导管动脉化疗栓塞术 (TACE) 的晚期肝细胞癌 (HCC) 的预后各不相同。本研究旨在评估血清载脂蛋白B（ApoB）/载脂蛋白AI（ApoA-I）对这组患者的预后价值。方法：通过术前常规血脂检查获得行 TACE 治疗的 HCC 患者的血脂水平。使用倾向评分匹配 (PSM) 分析来消除高和低 ApoB/ApoA-I 组基线特征的不平衡。然后，进行单变量和多变量分析以评估ApoB/ApoA-I的预后价值。结果：在接受 TACE 治疗的 455 名 HCC 患者中，ApoB/ApoA-I 与 AFP、T 分期、远处转移和 TNM 分期呈正相关（p #x3c；0.05）。与 ApoB/ApoA-I 低的患者相比，ApoB/ApoA-I 高的患者的总生存期 (OS) 显着缩短（中位 OS，21.7 个月与 39.6 个月，p #x3c；0.001）。多变量分析表明 ApoB/ApoA-I 是 OS 的独立预后指标（风险比 [HR] = 1.42，p = 0.008）。平衡基线特征后，288 名患者被纳入 PSM 队列。在该队列中，在单变量分析（中位 OS，27.6 个月与 39.3 个月，p = 0.002）和多变量分析（HR = 1.58，p = 0.006）中，高 ApoB/ApoA-I 仍预测较差的 OS 。结论：血清 ApoB/ApoA-I 是一种有用的生物标志物，可用于预测 TACE 治疗的 HCC 患者的侵袭性临床病理特征和不良预后。
肿瘤资源治疗